Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 1

Interventions

Nivolumab 24pembrolizumab 22Ipilimumab 17Specimen Handling 15Magnetic Resonance Spectroscopy 9CTLA-4 Antigen 8Opdualag 7relatlimab 6Cyclophosphamide 6binimetinib 5Paclitaxel 5trametinib 4fludarabine phosphate 4fludarabine 4cemiplimab 4Carboplatin 4Biopsy 4lifileucel 3dabrafenib 3atezolizumab 3X-Rays 3Taxes 3Standard of Care 3Radiotherapy 3Radiation 3Pemetrexed 3Introns 3Interferon alpha-2 3Immunoglobulin G 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
daromun × Dermatologic × 30 days × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡